|
|
Blood, 15 January 2005, Vol. 105, No. 2, pp. 650-658.
Prepublished online as a Blood First Edition Paper on September 14, 2004; DOI 10.1182/blood-2004-05-1714.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs
Silvia Muro,
Christine Gajewski,
Michael Koval, and
Vladimir R. Muzykantov
From the Institute for Environmental Medicine and Departments of Physiology and Pharmacology University of Pennsylvania School of Medicine, Philadelphia, PA.
Intercellular adhesion molecule-1 (ICAM-1) is a target for drug delivery to endothelial cells (ECs), which internalize multivalent anti-ICAM nanocarriers (anti-ICAM/NCs) within 15 to 30 minutes. The concomitant ICAM-1 disappearance from the EC surface transiently inhibited subsequent binding and uptake of anti-ICAM/NCs. Within 1 hour, internalized ICAM-1 diverged from anti-ICAM/NCs into prelysosomal vesicles, resurfaced, and enabled uptake of a subsequent anti-ICAM/NC dose. Thus, internalized ICAM-1 was able to recycle back to the plasma membrane. In vivo pulmonary targeting of a second anti-ICAM/NC dose injected 15 minutes after the first dose was decreased by 50% but recovered between 30 minutes and 2.5 hours, comparable to cultured ECs. Anti-ICAM/NCs affected neither EC viability nor fluid-phase endocytosis and traffic to lysosomes. However, lysosomal trafficking of the second dose of anti-ICAM/NCs was decelerated at least 2-fold versus the first dose; hence the major fraction of anti-ICAM/NCs resided in prelysosomal vesicles for at least 5 hours without degradation. Two successive doses of anti-ICAM/NC/catalase protected ECs against H2O2 for at least 8 hours versus 2 hours afforded by a single dose, suggesting that recurrent targeting to ICAM-1 affords longer effects. ICAM-1 recycling and inhibited lysosomal traffic/degradation of subsequent doses may help to prolong activity of therapeutic agents delivered into ECs by anti-ICAM/NCs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Garnacho, V. Shuvaev, A. Thomas, L. McKenna, J. Sun, M. Koval, S. Albelda, V. Muzykantov, and S. Muro
RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1
Blood,
March 15, 2008;
111(6):
3024 - 3033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rossin, S. Muro, M. J. Welch, V. R. Muzykantov, and D. P. Schuster
In Vivo Imaging of 64Cu-Labeled Polymer Nanoparticles Targeted to the Lung Endothelium
J. Nucl. Med.,
January 1, 2008;
49(1):
103 - 111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Patschan, J. Chen, O. Gealekman, K. Krupincza, M. Wang, L. Shu, J. A. Shayman, and M. S. Goligorsky
Mapping mechanisms and charting the time course of premature cell senescence and apoptosis: lysosomal dysfunction and ganglioside accumulation in endothelial cells
Am J Physiol Renal Physiol,
January 1, 2008;
294(1):
F100 - F109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Muro, T. Dziubla, W. Qiu, J. Leferovich, X. Cui, E. Berk, and V. R. Muzykantov
Endothelial Targeting of High-Affinity Multivalent Polymer Nanocarriers Directed to Intercellular Adhesion Molecule 1
J. Pharmacol. Exp. Ther.,
June 1, 2006;
317(3):
1161 - 1169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Stan
Endocytosis pathways in endothelium: how many?
Am J Physiol Lung Cell Mol Physiol,
May 1, 2006;
290(5):
L806 - L808.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Muro, M. Mateescu, C. Gajewski, M. Robinson, V. R. Muzykantov, and M. Koval
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins
Am J Physiol Lung Cell Mol Physiol,
May 1, 2006;
290(5):
L809 - L817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-S. Ding, T. Dziubla, V. V. Shuvaev, S. Muro, and V. R. Muzykantov
Advanced drug delivery systems that target the vascular endothelium.
Mol. Interv.,
April 1, 2006;
6(2):
98 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
